Related Experiment Videos
Management of multiple myeloma.
1Division of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock 72205.
Blut
|January 1, 1990
Summary
Multiple myeloma treatment shows limited progress, with a 3-year survival rate. Allogeneic bone marrow transplantation offers a potential cure, achieving a 30% survival plateau in clinical trials.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Multiple myeloma has a poor prognosis with limited treatment advancements.
- Current average survival for multiple myeloma patients is approximately 3 years.
Purpose of the Study:
- To review current therapeutic strategies for multiple myeloma.
- To explore novel treatment possibilities and concepts for improving patient outcomes.
Main Methods:
- Review of existing clinical trial data and therapeutic regimens.
- Discussion of potential future treatment modalities including transplantation and immunotherapy.
Main Results:
- Allogeneic bone marrow transplantation demonstrates potential for disease control, achieving a 30% survival plateau.
- Sequential use of established regimens and novel agents like interleukin-2 show promise.
Conclusions:
- Significant therapeutic advances are emerging, but clinical trials are in early stages.
- Novel concepts and immunoconjugate therapy offer hope for improving the outlook for multiple myeloma patients.